Somatostatin analogues in oncological therapy

Mechanism of Action

Mechanisms of Action

1**. Receptor Binding:** Somatostatin analogues bind to specific somatostatin receptors (SST receptors) that are overexpressed in many neuroendocrine tumors. There are five known subtypes (SST1-5), with SST2 and SST5 being particularly relevant in NETs.

2. Inhibition of Hormone Secretion: These analogues inhibit the secretion of various hormones and growth factors produced by neuroendocrine tumors, such as serotonin, insulin, and glucagon. This helps alleviate symptoms associated with hormone hypersecretion (e.g., flushing, diarrhea).

3. Antiproliferative Effects: Somatostatin analogues exhibit antiproliferative effects by inducing cell cycle arrest and apoptosis (programmed cell death) in tumor cells. This is mediated through the activation of signaling pathways such as the inhibition of cyclic AMP (cAMP) and the modulation of mitogen-activated protein (MAP) kinase pathways.

4. Antiangiogenic Properties: These agents may also inhibit tumor angiogenesis (the formation of new blood vessels) by downregulating vascular endothelial growth factor (VEGF) and other pro-angiogenic factors, limiting the tumor's ability to grow and metastasize.

5. Symptom Control: By reducing hormone levels and tumor burden, somatostatin analogues can significantly improve the quality of life for patients, leading to better symptom management in conditions like carcinoid syndrome.



Octreotide



Lanreotide



Clinical Implications

1.Therapeutic Use: Somatostatin analogues such as octreotide and lanreotide are commonly used in the treatment of functional NETs, providing both symptomatic relief and tumor growth control.

2. Long-Term Management: They are also used as long-term management strategies for patients with metastatic NETs, improving overall survival rates compared to supportive care alone.

3. Common Examples:

Octreotide: Often used for acromegaly and to control symptoms of neuroendocrine tumors.

Lanreotide: Similar uses as octreotide, often administered as an injection.

Clinical Efficacy

Evidence Supporting Somatostatin Analogues

1. Symptom Relief:

Clinical Trials: Numerous studies have shown that somatostatin analogues, particularly octreotide and lanreotide, effectively reduce the frequency and severity of symptoms associated with carcinoid syndrome, such as flushing and diarrhea.

Meta-analyses: Systematic reviews and meta-analyses confirm that somatostatin analogues can significantly decrease symptom burden and improve quality of life in patients with carcinoid tumors.

2. Hormonal Control:

Serotonin Levels: Somatostatin analogues have been shown to reduce plasma serotonin levels in patients, which correlates with symptom improvement. Decreased serotonin levels lead to reduced flushing and diarrhea.

Long-term Efficacy: Longitudinal studies indicate sustained symptom control over extended periods, often leading to a reduction in the need for supportive medications.

3. Quality of Life:

Patient-Reported Outcomes: Surveys and studies measuring quality of life have shown marked improvements in patients receiving somatostatin analogue therapy, highlighting the positive impact on daily functioning and overall well-being.



FIG. 2. Scatter plots of serum serotonin levels and serum biochemical turnover markers at



Comparison to Other Treatment Modalities

1. Supportive Care:

Symptom Management: While supportive care measures (such as antidiarrheal agents) can be effective for symptom control, they do not address the underlying hormonal hypersecretion or tumor growth. Somatostatin analogues provide a more targeted approach.

2. Chemotherapy:

Efficacy: Chemotherapy (e.g., streptozocin, temozolomide) can be used for advanced NETs but is typically reserved for more aggressive disease or when somatostatin analogues are insufficient. Chemotherapy may have more significant side effects compared to somatostatin analogues.

3. Targeted Therapies:

Everolimus and Sunitinib: These targeted agents can be effective in controlling tumor growth but may not provide the same immediate symptom relief as somatostatin analogues. They are often used in more advanced cases or when somatostatin analogues fail.

4. Surgery:

Curative Intent: Surgical resection of primary tumors or metastases can offer a potential cure for localized disease. However, in cases of metastatic carcinoid syndrome, somatostatin analogues are often used postoperatively to manage symptoms.

Side Effects and Tolerance:

Common Side Effects

1. Gastrointestinal Issues:

Nausea and Vomiting: Some patients may experience nausea or vomiting, particularly with initial dosing.

Diarrhea: Paradoxically, while somatostatin analogues help manage diarrhea in carcinoid syndrome, they can also cause gastrointestinal distress in some patients.

Abdominal Pain: Patients may report abdominal cramping or discomfort.

2. Endocrine Effects:

Hyperglycemia: Somatostatin analogues can affect glucose metabolism, potentially leading to increased blood sugar levels.

Hypothyroidism: There is a risk of thyroid hormone suppression, which may require monitoring and management.

3. Injection Site Reactions:

Local Reactions: Patients may experience pain, redness, or swelling at the site of injection, which can be bothersome.

4. Fatigue:

Generalized Fatigue: Some patients report feelings of fatigue or malaise, which can impact daily activities and overall well-being.

5. Cholelithiasis:

Gallbladder Issues: Prolonged use of somatostatin analogues may increase the risk of gallstone formation due to reduced gallbladder motility.

Table 2: Associated Side Effects with Somatostatin Analogues

Secondary effect with octreotide	Constipation Flatulence
Frequent (in about 10 % of patients taking octreotide)	Diarrhoea Nausea Abdominal pain Gallstones
Rare (in less than 1 % of patient taking SSA)	Glucose intolerance Hair loss Steatorrhoea Loss of appetite Itching Skin rash Thyroid problems

SSA – somatostatin analogue

Table 3. Reported side effects of somatostatin analogues.

Side effects	References
Hepatitis, cholestasis and gallstones	Demirbilek *et al.*,[179] Levy-Khademi *et al.*,[216] Avatapalle *et al.*,[162] Ben-Ari *et al.*,[77] Malik *et al.*,[181] Koren *et al.*,[78] Radetti *et al.*,[174] Glaser *et al.*[139]
Necrotizing enterocolitis	Laje *et al.*,[238] Hawkes *et al.*,[134] Abdel Khalek and Kandil[138] Alsaedi *et al.*,[150] McMahon *et al.*,[109] Reck-Burneo *et al.*[229]
Tachyphylaxis	Thornton *et al.*,[3] Hawdon *et al.*[136]
Inhibition of other hormones	Aynsley-Green *et al.*[69]
Gastrointestinal dysmotility	Glaser *et al.*[139]
Paradoxical hyperglycaemia and bradycardia	Batra *et al.*[173]
Prolonged QT interval	Celik *et al.*[83]
Deceleration of growth	Yorifuji *et al.*[113]
Seizure after stopping octreotide	Bas *et al.*[149]

Impact on Patient Quality of Life

1. Symptom Management: While somatostatin analogues effectively control symptoms of carcinoid syndrome, the side effects can counteract some of the benefits, particularly gastrointestinal issues and fatigue, leading to fluctuations in overall quality of life.

2. Daily Activities: Side effects such as nausea, abdominal pain, and fatigue can hinder patients' ability to engage in daily activities, work, and maintain social relationships, which is critical for emotional well-being.

3. Psychological Impact: The presence of side effects can lead to increased anxiety or depression in some patients, particularly if they affect independence or lead to significant lifestyle changes.

4. Adherence to Treatment: The occurrence of side effects can impact a patient's willingness to continue therapy, thus affecting long-term treatment efficacy. Managing side effects is essential to ensure adherence to somatostatin analogue therapy.

Combination Therapies

Chloe's draft



1. Synergistic Effects with Chemotherapy

Combination with Cytotoxic Agents: Somatostatin analogues may be used alongside standard chemotherapy regimens (e.g., FOLFOX, CAPOX) to enhance therapeutic efficacy. For instance, they can help reduce chemotherapy-related side effects or improve tolerance, allowing for higher doses or more frequent administration.

Mitigating Tumor Growth: By inhibiting hormone secretion and tumor growth, somatostatin analogues can complement the effects of chemotherapy, potentially leading to improved progression-free survival rates.

2. Targeted Therapies

Use with Targeted Agents: Somatostatin analogues can be combined with targeted therapies such as everolimus (an mTOR inhibitor) or sunitinib (a tyrosine kinase inhibitor). These combinations can target different pathways involved in tumor growth and angiogenesis, potentially leading to improved outcomes.

Sequential Therapy: Initial treatment with somatostatin analogues can stabilize disease and alleviate symptoms, followed by the introduction of targeted therapies to enhance tumor response.

3. Radiolabeled Somatostatin Analogs

Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin analogues can be labeled with radioactive isotopes (e.g., lutetium-177) for targeted radiotherapy. This approach directly delivers radiation to tumor cells expressing somatostatin receptors, potentially improving therapeutic outcomes in advanced NETs.

Combination with Chemotherapy or Targeted Therapy:PRRT can be integrated into a broader treatment plan that includes chemotherapy or targeted agents for synergistic effects, particularly in refractory cases.

4. Immunotherapy

Enhancing Immune Response: Research is ongoing to explore the potential of combining somatostatin analogues with immunotherapies (e.g., checkpoint inhibitors). Somatostatin analogues may enhance the immune response by modulating the tumor microenvironment, potentially making tumors more susceptible to immunotherapy.

5. Hormonal Therapy

Management of Hormonal Secretion: In tumors that produce various hormones, somatostatin analogues can be integrated into treatment regimens to manage symptoms and hypersecretion. This can improve patient quality of life while other therapies target tumor growth.

6. Palliative Care

Symptom Management:In advanced gastrointestinal cancers, somatostatin analogues can be used in combination with palliative treatments to control symptoms such as pain, diarrhea, and hormonal syndromes, thus improving the overall quality of life.



Influence on the Tumor Microenvironment

1. Modulation of Cell Signaling

Inhibition of Growth Factors: Somatostatin analogues inhibit the secretion of various growth factors and hormones (e.g., insulin, glucagon) that can promote tumor growth and angiogenesis.

Receptor Expression: These analogues can alter the expression of somatostatin receptors (SSTRs) on tumor cells and surrounding stroma, potentially enhancing tumor sensitivity to therapy.

2. Effects on Angiogenesis

Reduced Angiogenic Factors: Somatostatin analogues can decrease the production of pro-angiogenic factors like vascular endothelial growth factor (VEGF), leading to reduced blood supply to the tumor and limiting its growth.

Normalization of Blood Vessels: By reducing abnormal angiogenesis, these agents may help normalize the blood vessel structure within the TME, potentially improving drug delivery and efficacy.

3.Immune Modulation

Immune Cell Infiltration: Somatostatin analogues can influence the infiltration and activity of immune cells (e.g., T cells, macrophages) within the TME, promoting a more favorable immune response against the tumor.

Cytokine Balance: They may help shift the balance of cytokines in the TME, enhancing anti-tumor immunity while potentially reducing immunosuppressive signals.

4. Stromal Interactions

Impact on Fibroblasts: Somatostatin analogues can affect the behavior of cancer-associated fibroblasts (CAFs), which play a crucial role in tumor progression and therapy resistance.

Extracellular Matrix Remodeling: By modulating ECM components, somatostatin analogues may alter the physical and biochemical properties of the TME, impacting tumor invasion and metastasis.